---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022753"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:44:40.778624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK

## Summary
- Net revenue $11.7M vs $8.5M prior year, 38% increase.
- Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.
- Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.
- Vibativ approved in China; launch expected by end of 2025.
- Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M.

## SEC filing metadata
- accession: 0001628280-25-022753
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/0001628280-25-022753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/cpix-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022753
- JSON: https://secwatch.observer/filing/0001628280-25-022753.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.